Kindeva To Supply DuoDote® Antidote For U.S. Emergency Stockpile Under $129M Contract

Kindeva Drug Delivery's global health division, Meridian Medical Technologies, has signed a contract worth $129 million. Kindeva, known for its expertise in drug delivery devices. This agreement underscores the supply of DuoDote® autoinjectors to the U.S. Strategic National Stockpile. This program, managed by the Department of Health and Human Services, helps prepare the nation for emergencies. 

DuoDote® is an FDA-approved device that combines two medicines, atropine and pralidoxime chloride, into a single autoinjector. It’s used to treat poisoning caused by certain nerve agents and insecticides.The autoinjectors will be made at Kindeva’s facility in St. Louis, Missouri, and distributed across the country to ensure they’re ready to be promptly supplied if needed. 

Milton Boyer, CEO of Kindeva, said in a statement, “Kindeva is a global force in medical countermeasure development, manufacturing, and supply. As a trusted partner to the SNS, this contract underscores the ongoing importance of maintaining readiness against potential threats.” 

Milton Boyer also said,  “Our long-standing partnership with the SNS reflects our commitment to national preparedness and our ability to deliver crucial medical countermeasures when they are needed most. With our extensive experience in this space, we are proud to continue supporting the U.S. government’s efforts to protect public health and safety.”